Prana Biotechnology (PBT) announced that it has secured a key PBT2 patent in Japan. The Japanese Patent Office has granted a composition of matter patent for Prana’slead clinical asset, PBT2 and other selected 8-Hydroxyquinoline compounds in Japan. The patent entitled ‘8-Hydroxyquinoline derivatives’ also covers pharmaceutical compositions containing PBT2 and selected 8-hydroxyquinoline compounds and the use of the compounds for the treatment of Alzheimer’s Disease. The Japanese patent has a twenty year term expiring on 16 July 2023, with a possible extension of term of up to 5 years under pharmaceutical protection provisions.
Geoffrey Kempler, Prana’s Executive Chairm an, said “This decision by the Japanese Office to grant a claim to PBT2 completes a suite of core patent rights protecting this asset in key markets including the United States, Europe, Japan and Australia, further bolstering our commercialization plans in both Huntington’s and Alzheimer’s Disease”.
Prana Biotechnology was established to commercialize research into age-related neurodegenerative disorders.